SCHEMBL632045

SCHEMBL632045

CN(C)c1ccc(C(N)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.67
MAPT P10636 3/20 0.67
HPGD P15428 2/20 0.67
RAB9A P51151 3/20 0.57
NPC1 O15118 3/20 0.57
ALOX15 P16050 3/20 0.52
TSHR P16473 3/20 0.52
HSD17B10 Q99714 2/20 0.52
MAPK1 P28482 3/20 0.52
CYP3A4 P08684 3/20 0.52
HBB P68871 1/20 0.52
POLB P06746 3/20 0.52
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
TDP1 Q9NUW8 3/20 0.50
CA2 P00918 2/20 0.50
PARP10 Q53GL7 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6712807 0.88 NPC1 (0.71) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL6712805 0.88 NPC1 (0.71) ALDH1A1MAPTHPGDRAB9ANPC1
Trifluoroacetic Acid SCHEMBL6436696 0.87 MAPT (0.52) ALDH1A1MAPTHPGDRAB9ANPC1
Terephthalamide SCHEMBL27683041 0.85 PARP10 (0.58) ALDH1A1MAPTTSHRHSD17B10CYP3A4
SCHEMBL16168831 0.84 PARP10 (0.48) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL8686665 0.82 PARP10 (0.47) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL23079023 0.81 ALDH1A1 (0.67) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL195618 0.81 ALDH1A1 (0.67) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL3205714 0.80 SMN1; SMN2 (0.49) ALDH1A1MAPTHPGDRAB9ANPC1
SCHEMBL194888 0.80 RAB9A (0.83) ALDH1A1MAPTHPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119842323-A CMP composition for obtaining high-quality SiC monocrystal substrate surface and preparation method thereof 郑州磨料磨具磨削研究所有限公司 2025-04-18 CN claimed
CN-119798223-A (1H-indazol-5-yl) amino-2-pyridine derivative and application thereof 沈阳药科大学 2025-04-11 CN claimed
WO-2025072664-A1 NOVEL SMALL MOLECULE INHIBITORS OF TOPBP1-BRCT7/8 THAT EXERT ANTI-MYC ACTIVITY AND SYNERGY WITH INHIBITORS OF PARP1/2 AND PARP14 BAYLOR COLLEGE OF MEDICINE (US) 2025-04-03 WO claimed
CN-117136059-A Pharmaceutical composition containing JAK3/JAK1/TBK1 selective inhibitor and medical application thereof 深圳微芯生物科技股份有限公司 2023-11-28 CN claimed
CN-116555853-A Silver plating piece surface treatment method for improving pulling-out force by ultrasonic welding and silver plating terminal part 绵阳华丰互连技术有限公司 2023-08-08 CN claimed
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US claimed
CN-116218335-A Surface protection water-soluble protective agent and method 深圳市力达纳米科技有限公司 2023-06-06 CN claimed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP claimed
WO-2022222948-A1 PHARMACEUTICAL COMPOSITION CONTAINING JAK3/JAK1/TBK1 SELECTIVE INHIBITOR AND MEDICAL USE THEREOF 深圳微芯生物科技股份有限公司 2022-10-27 WO claimed
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
EP-1252157-B1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PROD INC (US) 2004-06-23 EP claimed
WO-2004043951-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS CAREX S.A. (FR) 2004-05-27 WO claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 WO claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES FCER2, FCGR2A, FCGR1A ALDH1A1 1433/4885MAPT 4114/4885HPGD 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.